Literature DB >> 6207117

Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize.

F Belardelli, M Ferrantini, C Maury, L Santurbano, I Gresser.   

Abstract

Cloned interferon-sensitive (745) and interferon-resistant (3Cl-8) Friend erythroleukemia cells (FLC) passaged in vitro, are not very tumorigenic when first injected intraperitoneally (i.p.) into syngeneic DBA/2 mice although they do form solid tumors when injected subcutaneously (s.c.). By serially passaging FLC (either 745 or 3Cl-8 cells) i.p. in DBA/2 mice, we obtained two different FLC lines capable of growing i.p. and inducing tumor ascites. The s.c. injection of DBA/2 mice with these in vivo passaged FLC resulted in tumor metastases in the liver and spleen, whereas metastases were not observed in mice inoculated s.c. with in vitro passaged FLC. The capacity of in vivo passaged FLC to metastasize was acquired after several i.p. passages. This highly malignant behavior was a stable characteristic of these cells. All the clones derived from in vivo passaged FLC and passaged more than 14 times in vitro induced hemorrhagic ascites when injected i.p., and metastasized to the liver and spleen when injected s.c. The phenotype of sensitivity or resistance to the inhibitory effect of alpha/beta mouse interferon on virus replication and cell multiplication was conserved during serial i.p. passages and maintained in the clones derived from in vivo passaged cells. These FLC showed a decreased capacity to differentiate in vitro upon treatment with dimethylsulfoxide (DMSO) and a reduced production of Friend leukemia virus with respect to the original clones passaged in vitro.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207117     DOI: 10.1002/ijc.2910340316

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Role of endogenous alpha/beta interferon in the selection of virus nonproducer Friend leukemia cells after serial intraperitoneal passages in syngeneic mice.

Authors:  M Ferrantini; F Belardelli; C Locardi
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Studies on the expression of H-2 antigens in non-metastatic and highly metastatic Friend erythroleukemia cells: correlation with the in vivo behaviour of tumor cells.

Authors:  M Ferrantini; S Pulciani; E Proietti; G Lespinats; A Anastasi; V Ciolli; P Rizza; F Belardelli
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

3.  Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver.

Authors:  G Elia; M Ferrantini; F Belardelli; E Proietti; I Gresser; C Amici; A Benedetto
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

Review 4.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

5.  Influence of the site of tumor growth on the capacity of a low tumorigenic line of Friend erythroleukemia cells to differentiate.

Authors:  I Gresser; J Moss; D Woodrow; C Le Bousse; C Maury; E Proietti; F Belardelli
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Authors:  L Gabriele; T Kaido; D Woodrow; J Moss; M Ferrantini; E Proletti; L Santodonato; C Rozera; C Maury; F Belardelli
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

7.  Natural resistance in mice against Friend cells injected intravenously. III. Comparison between in vivo and in vitro passaged interferon-sensitive (745) and interferon-resistant (3Cl8) cell clones.

Authors:  M Neri; T Zei; E Bonmassar; G B Rossi; G Fiorucci; A N Iorio
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

8.  Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice.

Authors:  I Gresser; C Carnaud; C Maury; A Sala; P Eid; D Woodrow; M T Maunoury; F Belardelli
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

9.  Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.

Authors:  V Ciolli; L Gabriele; P Sestili; F Varano; E Proietti; I Gresser; U Testa; E Montesoro; D Bulgarini; G Mariani
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

10.  Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice.

Authors:  I Gresser; C Maury; F Vignaux; O Haller; F Belardelli; M G Tovey
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.